ストックスクリーナーアプリを入手
0.551
0.18%
0.001
Pharmacyte Biotech Inc (PMCB) 最新ニュース
PharmaCyte Biotech Inc (PMCB) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
PharmaCyte Biotech Inc (PMCB) Stock News Today - tradingkey.com
PharmaCyte Biotech (PMCB) Q1 2026 Earnings: Narrowing Loss Amid Clinical ProgressHealthcare Earnings Report - dars.gov.et
PharmaCyte Biotech, Inc. FY 2026: Revenue $0 Net income ($23.21M), EPS ($2.77) — 10-K Summary - TradingView
PharmaCyte Biotech, Inc. Reports Earnings Results for the Full Year Ended April 30, 2026 - marketscreener.com
PharmaCyte Biotech Inc (PMCB) Financial Health: Profitability & Balance Sheet Analysis - tradingkey.com
PharmaCyte Biotech Inc (PMCB) Institutional Confidence - TradingKey
PharmaCyte Biotech Inc (PMCB) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
PharmaCyte Biotech Inc (PMCB) Balance Sheet - TradingKey
PharmaCyte Biotech Inc (PMCB) Cash Flow - TradingKey
PharmaCyte Biotech Inc (PMCB) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
PMCB|PharmaCyte Biotech Inc|Price:0.600|Chg%:-0.005 - TradingKey
PharmaCyte Biotech Inc (PMCB) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
PharmaCyte Biotech Inc (PMCB) Valuation: PE, PB & Fair Value Analysis - TradingKey
PharmaCyte Biotech Inc (PMCB) Income Statement - TradingKey
PMCB|PharmaCyte Biotech Inc|Price:0.576|Chg%:-0.024 - tradingkey.com
PMCB|PharmaCyte Biotech Inc|Price:0.611|Chg%:+0.035 - TradingKey
PharmaCyte Biotech, Inc. Revenue Breakdown – NASDAQ:PMCB - TradingView
PharmaCyte Biotech Inc (PMCB) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
PharmaCyte Biotech (PMCB) Slips 4% as Stock Tests Key Support Near $0.60New Highs New Lows - dars.gov.et
PharmaCyte Biotech | 4: Statement of changes in beneficial ownership of securities-Director SCHECHTER JONATHAN - Moomoo
- po-news-eg.net
[Form 4/A] PharmaCyte Biotech, Inc. Amended Insider Trading Activity - Stock Titan
PharmaCyte Biotech (PMCB) cancels erroneous stock option grant - Stock Titan
PharmaCyte Biotech (PMCB) amends Form 4 to cancel option grant - Stock Titan
PharmaCyte Biotech (PMCB) director corrects erroneous, cancelled option grant - Stock Titan
PharmaCyte Biotech (PMCB) Slides 6.6% as Biotech Selling Pressure PersistsDebt Free Companies - dars.gov.et
PharmaCyte Biotech (PMCB) Slides 1.4% Near Key Support Level at $0.66Adaptive Moving Average - dars.gov.et
PharmaCyte Biotech (PMCB) Holds Near Support as Modest Decline Tests Trader ConvictionGap Down Bounce Plays - dars.gov.et
PMCB Q1 2026 Earnings: Losses Narrow as Biotech Advances Pipeline Amid Positive Market SentimentROA Comparison - Bölüm Sonu Canavarı
PharmaCyte Biotech | SCHEDULE 13G: Others - Moomoo
PMCB Q1 2026 Earnings: Loss Per Share of $0.09 as Clinical Pipeline AdvancesEarnings Quality Score - po-news-eg.net
PharmaCyte Biotech | DEF 14A: Definitive information statements - Moomoo
PMCB Q1 2026 Earnings: Pre-Revenue Biotech Reports Slight Loss, Shares RiseEarnings Risk Report - dars.gov.et
Price to book forward of PharmaCyte Biotech, Inc. – NASDAQ:PMCB - TradingView
Price to sales forward of PharmaCyte Biotech, Inc. – NASDAQ:PMCB - TradingView
Price to earnings forward of PharmaCyte Biotech, Inc. – NASDAQ:PMCB - TradingView
Enterprise value to EBITDA forward of PharmaCyte Biotech, Inc. – NASDAQ:PMCB - TradingView
Enterprise value to revenue forward of PharmaCyte Biotech, Inc. – NASDAQ:PMCB - TradingView
PharmaCyte Biotech Inc (PMCB) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
PMCB Q1 2026 Earnings: Reported Loss of -$0.09 Per Share as Stock DeclinesAnalyst Consensus Shift - dars.gov.et
PMCB Q1 2026 Earnings: Pre-Revenue Biotech Reports Net Loss, Shares Slide 8%Strong Earnings Momentum - dars.gov.et
PharmaCyte Biotech (PMCB) Holds Steady at $0.7: Consolidation Near Key SupportVolume Profile - newsline.com
PMCB Q1 2026 Earnings: Modest Loss Reported Amid Early-Stage DevelopmentEarnings Surprise Report - dars.gov.et
PMCB Technical Analysis & Stock Price Forecast - Intellectia AI
PMCB Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
PharmaCyte Biotech Inc. (PMCB) Q1 2026 Earnings: Pre‑Revenue Biotech Reports Loss, Shares Slide 3.5%Earnings Surprise Stocks - newsline.com
Tranche Update on PharmaCyte Biotech, Inc.'s Equity Buyback Plan announced on February 2, 2023. - marketscreener.com
PharmaCyte Biotech (PMCB) Rises 3.19%: Approaching Resistance Zone Amid Biotech Sector FocusChaikin Flow - newsline.com
PharmaCyte Biotech (PMCB) Slips 3.3% as Stock Nears Critical Support at $0.79Fundamental Weighted - dars.gov.et
PharmaCyte Biotech (PMCB) Jumps 12.76% as Biotech Speculation Heats UpBuyback Factor - The Legal Advocate
PMCBPharmaCyte Biotech Inc Stock Price and Quote - Finviz
PharmaCyte Biotech (PMCB) Edges Higher: Support-Holding Action at $0.81IPO Entry Watch - Newser
0.52%
0.07%
大文字化:
|
ボリューム (24 時間):